{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:02:05Z","timestamp":1792159325062,"version":"4.4.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)\u2013directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non\u2013small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This open-label phase II study evaluated T-DXd (5.4 mg\/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+\/2+ by local or central testing) locally advanced or metastatic disease after \u22651 systemic treatment or without alternative treatments. The primary end point was investigator-assessed confirmed objective response rate (ORR). Secondary end points included safety, duration of response, progression-free survival (PFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At primary analysis, 267 patients received treatment across seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other. The median follow-up was 12.75 months. In all patients, the ORR was 37.1% (n = 99; [95% CI, 31.3 to 43.2]), with responses in all cohorts; the median DOR was 11.3 months (95% CI, 9.6 to 17.8); the median PFS was 6.9 months (95% CI, 5.6 to 8.0); and the median OS was 13.4 months (95% CI, 11.9 to 15.5). In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6). Grade \u22653 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pretreated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.23.02005","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T10:49:14Z","timestamp":1698058154000},"page":"47-58","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1068,"title":["Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04482309","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9793-7614","authenticated-orcid":false,"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[{"name":"Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[{"name":"Gynaecologic Cancer Programme, Vall d\u2019Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital; Cancer Research Institute, Seoul National University College of Medicine; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8840-7934","authenticated-orcid":false,"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-9576","authenticated-orcid":false,"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Medical Oncology Department and Programme in Solid Tumours-CIMA, Cancer Center Cl\u00ednica Universidad de Navarra, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":false,"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"\u0141ugowska","sequence":"additional","affiliation":[{"name":"Early Phase Clinical Trials Unit and Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-550X","authenticated-orcid":false,"given":"Luis","family":"Manso","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Manzano","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Cancer (UTEC), Department of Medical Oncology, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Palack\u00fd University Medical School and University Hospital, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-2846","authenticated-orcid":false,"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[{"name":"Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda and the Department of Oncology and Hemato-Oncology, Universit\u00e0 degli Studi di Milano, Piazza dell\u2019Ospedale Maggiore, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-1092","authenticated-orcid":false,"given":"Daniil","family":"Stroyakovskiy","sequence":"additional","affiliation":[{"name":"Healthcare Department, Moscow City Oncology Hospital No. 62, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitra","family":"Fielding","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Puvvada","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Shire","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-1350","authenticated-orcid":false,"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112065"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9552-6"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01716-y"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0268-3"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02124"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02331"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00519"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0149"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092678"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S157092"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1014"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0331-CP"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathog.2015.05.002"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3151"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3014"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000599"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4006"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100553"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040614"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.23.02005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T18:00:59Z","timestamp":1703181659000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.02005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"alternative-id":["10.1200\/JCO.23.02005"],"URL":"https:\/\/doi.org\/10.1200\/jco.23.02005","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"assertion":[{"value":"2023-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}